Cochlear's proposed acquisition of Oticon Medical raises preliminary competition concerns* The ACCC has outlined significant preliminary competition concerns with Cochlear’s (ASX:COH) proposed acquisition of Oticon Medical in a statement of issues published today. Cochlear is proposing to acquire shares in and certain assets of Demant’s hearing implants business, Oticon Medical. Cochlear and Oticon Medical manufacture and supply non-surgical bone conduction devices, surgical bone anchored devices, and cochlear implant hearing devices. These devices are used to treat more advanced hearing loss that typically cannot be managed by hearing aids. There are few suppliers of these devices globally. In Australia, Cochlear and Oticon Medical are two of only three suppliers of
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.